Association of aberrations in one-carbon metabolism with molecular phenotype and grade of breast cancer

Molecular Carcinogenesis

Volumn 51, Issue SUPPL. 1, 2012, Pages

  Naushad, Shaik Mohammad ^a   Pavani, Addepalli ^a   Rupasree, Yedluri ^a   Divyya, Shree ^a   Deepti, Sripurna ^a   Digumarti, Raghunadha Rao ^a   Gottumukkala, Suryanarayana Raju ^a   Prayaga, Aruna ^a   Kutala, Vijay Kumar ^a  

^a NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Breast cancer; Estrogen receptor (ER); Human epidermal growth factor receptor 2 (HER2 Neu); One carbon metabolism; Phenotype; Plasma folate; Plasma homocysteine; Polymorphism; Progesterone receptor (PR)

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; GLYCINE HYDROXYMETHYLTRANSFERASE; HOMOCYSTEINE; METHIONINE SYNTHASE; REDUCED FOLATE CARRIER; THYMIDYLATE SYNTHASE;

5' UNTRANSLATED REGION; ABERRANT ONE CARBON METABOLISM; AMINO ACID BLOOD LEVEL; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ARTICLE; BODY MASS; BREAST CANCER; CANCER CLASSIFICATION; CARBON METABOLISM; CONTROLLED STUDY; DISEASE COURSE; FAMILIAL CANCER; FAMILY HISTORY; FOLIC ACID BLOOD LEVEL; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; ONSET AGE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TANDEM REPEAT;

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; BODY MASS INDEX; BREAST NEOPLASMS; CARBON; CASE-CONTROL STUDIES; ENZYMES; FEMALE; FOLIC ACID; GLYCINE HYDROXYMETHYLTRANSFERASE; HUMANS; MENOPAUSE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; THYMIDYLATE SYNTHASE;

EID: 84867143584     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21830     Document Type: Article

References (38)

1. Ford D, Easton DF. The genetics of breast and ovarian cancer. Br J Cancer 1995; 72: 805-812.
2. Mangia A, Tommasi S, Bruno M, et al. Histological features of extratumoral breast lesions as a predictive factor of familial breast cancer. Oncol Rep 2010; 23: 1641-1645.
3. Han SH, Lee KR, Lee DG, et al. Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer. Clin Genet 2006; 70: 496-501.
4. Snell C, Krypuy M, Wong EM, et al. BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res 2008; 10: R12.
5. Elsheikh S, Green AR, Aleskandarany MA, et al. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat 2008; 109: 325-335.
6. Fukino K, Shen L, Patocs A, et al. Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. JAMA 2007; 297: 2103-2111.
7. Chunder N, Mandal S, Roy A, Roychoudhury S, Panda CK. Differential association of BRCA1 and BRCA2 genes with some breast cancer-associated genes in early and late onset breast tumors. Ann Surg Oncol 2004; 11: 1045-1055.
8. Goode EL, Dunning AM, Kuschel B, et al. Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res 2002; 62: 3052-3057.
9. Xu X, Gammon MD, Zhang H, et al. Polymorphisms of one-carbon-metabolizing genes and risk of breast cancer in a population-based study. Carcinogenesis 2007; 28: 1504-1509.
10. Lee SA, Kang D, Nishio H, et al. Methylenetetrahydrofolate reductase polymorphism, diet, and breast cancer in Korean women. Exp Mol Med 2004; 36: 116-121.
11. Chen J, Gammon MD, Chan W, et al. One-carbon metabolism, MTHFR polymorphisms, and risk of breast cancer. Cancer Res 2005; 65: 1606-1614.
12. Sharp L, Little J, Schofield AC, et al. Folate and breast cancer: The role of polymorphisms in methylenetetrahydrofolate reductase (MTHFR). Cancer Lett 2002; 181: 65-71.
13. Chou YC, Wu MH, Yu JC, et al. Genetic polymorphisms of the methylenetetrahydrofolate reductase gene, plasma folate levels and breast cancer susceptibility: A case-control study in Taiwan. Carcinogenesis 2006; 27: 2295-2300.
14. Beilby J, Ingram D, Hahnel R, Rossi E. Reduced breast cancer risk with increasing serum folate in a case-control study of the C677T genotype of the methylenetetrahydrofolate reductase gene. Eur J Cancer 2004; 40: 1250-1254.
15. Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv Cancer Res 1998; 72: 141-196.
16. Christensen BC, Kelsey KT, Zheng S, et al. Breast cancer DNA methylation profiles are associated with tumor size and alcohol and folate intake. PLoS Genet 2010; 6: e1001043.
17. Tao MH, Shields PG, Nie J, et al. DNA promoter methylation in breast tumors: No association with genetic polymorphisms in MTHFR and MTR. Cancer Epidemiol Biomarkers Prev 2009; 18: 998-1002.
18. Early breast cancer trialists' collaborative group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998; 351: 1451-1467.
19. Grieu F, Powell B, Beilby J, Iacopetta B. Methylenetetrahydrofolate reductase and thymidylate synthase polymorphisms are not associated with breast cancer risk or phenotype. Anticancer Res 2004; 24: 3215-3219.
20. Li SY, Rong M, Iacopetta B. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in human breast cancer. Oncol Rep 2006; 15: 221-225.
21. Naushad SM, Pavani A, Digumarti RR, Gottumukkala SR, Kutala VK. Epistatic interactions between loci of one-carbon metabolism modulate susceptibility to breast cancer. Mol Biol Rep 2011; 38: 4893-4901.
22. Mohammad NS, Yedluri R, Addepalli P, Gottumukkala SR, Digumarti RR, Kutala VK. Aberrations in one-carbon metabolism induce oxidative DNA damage in sporadic breast cancer. Mol Cell Biochem 2011; 349: 159-167.
23. Iwase H, Itoh Y, Kuzushima T, et al. Simultaneous quantitative analyses of c-erbB-2 protein, epidermal growth factor receptor, cathepsin D, and hormone receptors in breast cancer. Cancer Detect Prev 1997; 21: 29-35.
24. Vijaya Lakshmi SV, Naushad SM, Rupasree Y, Seshagiri Rao D, Kutala VK. Interactions of 5'-UTR thymidylate synthase polymorphism with 677C→T methylene tetrahydrofolate reductase and 66A → G methyltetrahydrofolate homocysteine methyl-transferase reductase polymorphisms determine susceptibility to coronary artery disease. J Atheroscler Thromb 2011; 18: 56-64.
25. Yang XR, Sherman ME, Rimm DL, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007; 16: 439-443.
26. Larsson SC, Bergkvist L, Wolk A. Folate intake and risk of breast cancer by estrogen and progesterone receptor status in a Swedish cohort. Cancer Epidemiol Biomarkers Prev 2008; 17: 3444-3449.
27. Maruti SS, Ulrich CM, White E. Folate and one-carbon metabolism nutrients from supplements and diet in relation to breast cancer risk. Am J Clin Nutr 2009; 89: 624-633.
28. Heil SG, Van der Put NM, Waas ET, et al. Is mutated serine hydroxymethyltransferase (SHMT) involved in the etiology of neural tube defects? Mol Genet Metab 2001; 73: 164-172.
29. Pirouzpanah S, Taleban FA, Atri M, Abadi AR, Mehdipour P. The effect of modifiable potentials on hypermethylation status of retinoic acid receptor-beta2 and estrogen receptor-alpha genes in primary breast cancer. Cancer Causes Control 2010; 21: 2101-2111.
30. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Atlas. USA: Springer; 2009.
31. Singletary SE, Connolly JL. Breast cancer staging: Working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 2006; 37-47 (quiz 50-31).
32. Xu X, Gammon MD, Wetmur JG, et al. Cancer Epidemiol Biomarkers Prev 2008; 17: 2109-2116.
33. Skibola CF, Smith MT, Hubbard A, et al. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood 2002; 99: 3786-3791.
34. Stankova J, Shang J, Rozen R. Antisense inhibition of methylenetetrahydrofolate reductase reduces cancer cell survival in vitro and tumor growth in vivo. Clin Cancer Res 2005; 11: 2047-2052.
35. Stanisławska-Sachadyn A, Mitchell LE, Woodside JV, et al. The reduced folate carrier (SLC19A1) c.80G>A polymorphism is associated with red cell folate concentrations among women. Ann Hum Genet 2009; 73: 484-491.
36. Ifergan I, Jansen G, Assaraf YG. The reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation. RFC as a double edged sword in folate homeostasis. J Biol Chem 2008; 283: 20687-20695.
37. Kawakami K, Omura K, Kanehira E. Watanabe Y. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 1999; 19: 3249-3252.
38. Li Y, Tian Z, Rizvi SM, et al. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis 2002; 5: 36-46.